Jasper Therapeutics (JSPR) has announced promising initial findings from its ongoing SPOTLIGHT Phase 1b/2a clinical trial, which examines the effects of subcutaneous briquilimab on adult patients suffering from cold urticaria or symptomatic dermographism. The company revealed that 14 out of 15 participants in both dosage groups showed a clinical response within six weeks of administration. Notably, in the 120mg dosage group, 83% of participants achieved a complete response. Briquilimab was well tolerated throughout the study.
Furthermore, Jasper has received regulatory approval to commence enrollment for a 180mg dosage group within the SPOTLIGHT study. The company anticipates presenting the complete findings of the SPOTLIGHT study in the first half of 2025.
